OncLive TV

Dr. Papadimitrakopoulou on Immunotherapy Combinations in Lung Cancer

March 28th 2017

Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses trials investigating combinations of immunotherapy regimens in lung cancer.

Dr. Smith Discusses CAR T Cells in Multiple Myeloma

March 28th 2017

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric androgen receptor (CAR) T-cell therapy in multiple myeloma.

Dr. Gajewski on Targets Being Explored in Melanoma

March 28th 2017

Thomas F. Gajewski, MD, PhD, professor of medicine at The University of Chicago Medicine, discusses what targets are currently being explored in patients with melanoma.

Dr. O'Shaughnessy on Role of Chemotherapy in Future TNBC Treatment

March 28th 2017

Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, Texas Oncology, and chair of The US Oncology Network, and 2016 Giant of Cancer Care in Community Outreach, discusses the future role of chemotherapy in the treatment landscape of triple-negative breast cancer.

Dr. Beddoe on Ongoing Trials for Patients With Cervical Cancer

March 28th 2017

Ann Marie Beddoe, MD, assistant professor, Obstetrics, Gynecology and Reproductive Science, Gynecologic Oncology, Mount Sinai Hospital, discusses ongoing clinical trials for patients with cervical cancer.

Dr. Spigel on Pembrolizumab/Chemo Combo in First-Line NSCLC

March 27th 2017

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the results of cohort G from the KEYNOTE-021 trial, which explored pembrolizumab (Keytruda) combined with pemetrexed/carboplatin as a frontline treatment for patients with nonsquamous non–small cell lung cancer (NSCLC).

Dr. Jagannath on Potential of Immunotherapy in Multiple Myeloma

March 27th 2017

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Cancer Center, discusses the potential impact of immunotherapy in multiple myeloma.

Dr. Kumar on Studies Investigating Venetoclax in Multiple Myeloma

March 27th 2017

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses studies investigating venetoclax (Venclexta) in patients with multiple myeloma.

Dr. Jackman on Overcoming Resistance to EGFR Inhibitors in Lung Cancer

March 27th 2017

David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses overcoming resistance to EGFR inhibitors in non–small cell lung cancer (NSCLC).

Experts Raise Awareness for Colorectal Cancer

March 25th 2017

Dr. Osborne on the Benefits of Dual-Targeted Therapy for HER2+ Breast Cancer

March 25th 2017

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the benefits of dual-targeted therapy for patients with HER2-positive breast cancer.

Dr. Husain on the Future of Monitoring T790M in Lung Cancer

March 24th 2017

Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses the future of monitoring the emergence of EGFR T790M circulating tumor DNA in urine from EGFR-mutated non–small cell lung cancer (NSCLC).

Dr. Evans on Challenges of Immunotherapy in Lung Cancer

March 24th 2017

Tracey L. Evans, MD, associate professor of Clinical Medicine at Penn Medicine, discusses the challenges associated with immunotherapy for the treatment of patients with lung cancer.

Dr. Jackson on Ongoing Challenges in Treating Patients With Multiple Myeloma

March 24th 2017

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses some of the ongoing challenges in the treatment of patients with multiple myeloma.

Dr. Swisher on Efficacy Results of ARIEL 2 Study in Ovarian Cancer

March 24th 2017

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the results of the ARIEL2 trial in patients in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a germline or somatic BRCA mutation.

Dr. Usmani on Mechanisms and Response Rates With Daratumumab in Myeloma

March 24th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the mechanisms of daratumumab (Darzalex) as well as the reported response rates in combination with other agents in multiple myeloma.

Dr. Thompson on the Future of Treatment in Multiple Myeloma

March 24th 2017

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses the future of treatment in multiple myeloma.

Dr. Dreicer on Abiraterone and Enzalutamide in Prostate Cancer

March 24th 2017

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses abiraterone acetate (Zytiga) and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Seiwert on Advice With Immunotherapy for Head and Neck Cancer

March 23rd 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, gives advice to community oncologists on administering immunotherapy to patients with head and neck cancer.

Dr. Kudchadkar on the FDA Approval of Avelumab in Merkel Cell Carcinoma

March 23rd 2017

Ragini Kudchadkar, MD, assistant professor, Department of Hematology and Medical Oncology, associate director, Hematology and Medical Oncology Fellowship Program-Clinical/Service, Emory University School of Medicine, discusses the FDA approval of avelumab for the treatment of patients with Merkel cell carcinoma.